Osaka, Japan, February 27, 2026 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that with respect to the marketing and co-promotion agreement (“the agreement”) for the selective SGLT2 inhibitor “Forxiga® 5 mg, 10 mg tablets” (generic name: dapagliflozin propylene glycolate hydrate; “Forxiga”) in Japan concluded with AstraZeneca K.K. (Headquarters: Osaka, Japan; President: Takafumi Horii; “AstraZeneca”) and AstraZeneca UK Limited (Cambridge, UK; President: Tom Keith-Roach; “ AZUK ”), Ono, AstraZeneca, and AZUK have concluded a memorandum as of February 27, 2026 on the transfer of the distribution and sales conducted by Ono in Japan to AstraZeneca and the termination of the co-promotion activities with Ono.

1. Reasons for termination of agreement:

   Based on the agreement entered into in December 2013, Ono has been responsible for the distribution and sales of Forxiga while conducting co-promotion activities with AstraZeneca following the marketing authorization approval in Japan in March 2014. Extensive discussions between the parties in light of the changes in the market environment, including the launch of generic products for type 2 diabetes in December 2025, have led the companies to agree to terminate the agreement.

2. Details of termination of the agreement:

   Following the necessary procedures, the agreement will terminate on March 31, 2026, and the distribution, sales and promotion activities previously conducted by Ono in Japan will be transferred to AstraZeneca, and AstraZeneca will be solely responsible for the marketing and promotion activities. Moving forward, both Ono and AstraZeneca will cooperate to ensure a smooth transition, as well as continue to ensure a stable supply, provide and collect product information, and promote the proper use of Forxiga until the transfer is completed.

3. Products to be transferred:

   Forxiga® 5mg tablet
   Forxiga® 10mg tablet
   Forxiga is a selective SGLT2 inhibitor indicated for the treatment of type 2 diabetes, type 1 diabetes, chronic heart failure, and chronic kidney disease.

4. Overview of the company with whom the agreement is to be terminated:

   ＜Overview of AstraZeneca K.K.＞

   Name	AstraZeneca K.K.
   Location	Grand Front Osaka Tower B, 3-1 Ofukacho, Kita-ku, Osaka
   Representative’s title and name	Takashi Horii, President
   Business scope	Development, manufacturing and marketing of prescription drugs
   Capital	2 billion yen
   Incorporated on	11th April 1975
   Ono’s ties with AstraZeneca K.K.	Capital ties: None
   	Personnel ties: None
   	Business ties: Distribution and marketing alliance and co-promotion of Forxiga in Japan

   ＜Overview of AstraZeneca UK Limited＞

   Name	AstraZeneca UK Limited
   Location	1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK
   Representative’s title and name	Tom Keith-Roach, President
   Business scope	Development, manufacturing and marketing of prescription drugs
   Capital	Undisclosed
   Incorporated on	26th November 1998
   Ono’s ties with AstraZeneca UK Limited	Capital ties: None
   	Personnel ties: None
   	Business ties: Distribution and marketing alliance and co-promotion of Forxiga in Japan

5. Schedule

   Date of execution of the memorandum regarding the termination of the agreement	February 27, 2026
   Termination date of the agreement	March 31, 2026

6. Future outlook:

   • Ono anticipates a minimal impact on its business performance for the current fiscal year.
   • Ono will not accrue any sales revenue from Forxiga after April 1, 2026.
     Sales forecast for the fiscal year ending March 2026 is 80 billion Japanese yen (as of February 2, 2026, 3Q financial results announcement for the fiscal year ending March 2026).
   • Although Ono is unable to disclose the operating profit of Forxiga as a standalone product, Ono anticipates the impact on its operating profit in sales revenue for the fiscal year ending March 2027 to be limited, given that generic products were launched in December 2025.
   • Ono plans to disclose the details of the impact on its business performance for the fiscal year ending March 2027 and incorporate the details into its earnings forecasts in the consolidated financial results for the fiscal year ending March 31, 2026.